NRXP — NRX Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $24.93m
- $30.39m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +983.81 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 18th, 2017
- Public Since
- November 20th, 2017
- No. of Shareholders
- 56
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,700,609
- Address
- 1201 ORANGE STREET, SUITE 600, WILMINGTON, 19801
- Web
- https://www.nrxpharma.com/
- Phone
- +1 4842546134
- Contact
- Ryan Sheffield
- Auditors
- KPMG LLP
Upcoming Events for NRXP
Q2 2024 NRX Pharmaceuticals Inc Earnings Release
Q3 2024 NRX Pharmaceuticals Inc Earnings Release
NRX Pharmaceuticals Inc Annual Shareholders Meeting
Similar to NRXP
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the NRX Pharmaceuticals share price?
As of Today at 22:24 UTC, shares in NRX Pharmaceuticals are trading at $2.65. This share price information is delayed by 15 minutes.
How has the NRX Pharmaceuticals share price performed this year?
Shares in NRX Pharmaceuticals last closed at $2.65 and the price had moved by -49.04% over the past 365 days. In terms of relative price strength the NRX Pharmaceuticals share price has underperformed the S&P500 Index by -59.45% over the past year.
What are the analyst and broker recommendations for NRX Pharmaceuticals?
The overall consensus recommendation for NRX Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the NRX Pharmaceuticals dividend yield?
NRX Pharmaceuticals does not currently pay a dividend.
Does NRX Pharmaceuticals pay a dividend?
NRX Pharmaceuticals does not currently pay a dividend.
When does NRX Pharmaceuticals next pay dividends?
NRX Pharmaceuticals does not currently pay a dividend.
How do I buy NRX Pharmaceuticals shares?
To buy shares in NRX Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of NRX Pharmaceuticals?
As of the previous close price of $2.65, shares in NRX Pharmaceuticals had a market capitalisation of $28.36m.
Where are NRX Pharmaceuticals shares listed?
Here are the trading details for NRX Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NRXP
What kind of share is NRX Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum NRX Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a NRX Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in NRX Pharmaceuticals is $31.50. That is 1088.68% above the last closing price of $2.65.
Analysts covering NRX Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$3.21 for the next financial year.
What is the trend in the NRX Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NRX Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -48.77%.
As of the last closing price of $2.65, shares in NRX Pharmaceuticals were trading -28.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the NRX Pharmaceuticals PE Ratio?
The NRX Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of NRX Pharmaceuticals?
We do not have data on NRX Pharmaceuticals' directors